Roche Licenses Nurix’s BTK Degrader Bexobrutideg in Up to $2.3 Billion Deal

Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics for bexobrutideg (NX-5948), an oral Bruton’s Tyrosine Kinase (BTK) degrader. The deal, valued at up to $2.3 billion, adds a Phase 3-ready asset to Roche’s hematology pipeline while extending development opportunities into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS).

BTK-directed therapies remain central to the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. However, many patients eventually experience disease progression due to acquired resistance mutations, incomplete pathway suppression, or treatment intolerance, leaving a significant unmet need in later-line settings.

Novel BTK Degradation Strategy

Unlike conventional BTK inhibitors, bexobrutideg eliminates the BTK protein itself through targeted protein degradation. This approach removes both the kinase and scaffolding functions of BTK and may help overcome resistance mechanisms, including acquired mutations associated with current BTK inhibitor therapies.

The investigational agent is orally administered and brain-penetrant, supporting potential applications beyond oncology. Because BTK acts as a critical signaling molecule across multiple immune cell populations, its degradation may offer therapeutic benefits in immune-mediated and neurological disorders such as CSU and MS.

 Clinical Development Path

Bexobrutideg is scheduled to enter Phase 3 testing in summer 2026 for second-line CLL. Available clinical data suggest the potential for improved efficacy and tolerability compared with current BTK inhibitors while addressing resistance mechanisms linked to disease progression.

Early clinical studies have demonstrated activity in relapsed or refractory B-cell malignancies, supporting advancement into late-stage development. Industry forecasts project the combined non-Hodgkin lymphoma and CLL market to reach approximately $41 billion by 2031, with BTK-directed therapies accounting for nearly $19 billion.

Clinical and Regulatory Perspectives

Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said the company views bexobrutideg as a potential advance for patients with difficult-to-treat blood cancers and other serious diseases. He highlighted the opportunity to accelerate development of a novel treatment approach across multiple therapeutic areas.

Nurix Chief Executive Officer Arthur T. Sands emphasized Roche’s global development capabilities and established hematology franchise, noting the potential to expand Phase 3 development, explore combination regimens, and advance the program into immunology and neurology indications.

Deal Structure and Commercial Plans

Nurix will receive $700 million upfront and could earn development, regulatory, and commercial milestone payments that bring the total value of the agreement to as much as $2.3 billion. Development costs will be shared, with Roche covering 60% and Nurix 40%.

In the United States, the companies will co-develop and co-commercialize bexobrutideg, sharing profits and losses equally. Roche will lead commercialization outside the U.S., while Nurix will receive tiered royalties ranging from the low- to high-teens.

The transaction remains subject to customary regulatory clearances, including Hart-Scott-Rodino review, and is expected to close during the third quarter of 2026.

 Regulatory Path Forward and Clinical Expansion

The collaboration positions bexobrutideg as a potential next-generation BTK-targeted therapy across oncology, immunology, and neurology. With Phase 3 testing in second-line CLL expected to begin in summer 2026, upcoming studies will evaluate whether BTK degradation can overcome resistance mechanisms that limit current BTK inhibitors and provide a new treatment option for patients facing disease progression.

Reference

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology | Nurix Therapeutics, Inc.